Foreign investment and international plant configuration: whither the product cycle?.

We analyze the determinants of the decision to invest abroad in particular configurations of overseas plants for 120 Japanese firms active in 36 well-defined electronic product markets. We find support for a structured internationalization decision model in which the decision to produce abroad and the choice for a specific international plant configuration are treated as nested strategic options. Drivers at the industry and firm level push firms to consider overseas investment, and locational characteristics pull firms towards particular plant configurations. The product cycle still appears as an important force pushing firms to set up Asia-focused or global plant configurations. In contrast, plant configurations focused on the US and the EU are a result of restrictive trade policies or offensive market access considerations vital to technology intensive firms facing competitive threats in foreign markets.Foreign investment; International; Investment; Product; Markets; Model; Options; Industry; Characteristics; Trade; Trade policy;

Research and Development in Foreign Affiliates: Evidence from Japanese Firms

This paper analyzes the determinants of the R&D intensity of 434 foreign affiliates, drawing on MITI''s benchmark survey of Japanese multinational firms in 1993. Acquired affiliates are responsible for more than half of overseas R&D expenditure and have significantly higher R&D intensities than wholly and majority owned greenfield affiliates. Non-majority owned joint ventures are R&D intensive in case the investing firm lacks substantial R&D capabilities in Japan. In contrast, R&D intensive Japanese parent firms prefer controlled modes of overseas R&D investment. Support is also found for an incremental growth pattern of foreign R&D operations as a function of cumulative learning. This learning is affiliate-specific rather than firm-wide and applies to greenfield affiliates but not to acquired affiliates. The results provide evidence that Japanese multinational firms, as ‘latecomers’ in the establishment of overseas R&D networks, have often made use of acquisitions and collaborative ventures to gain access to overseas technology and to establish overseas R&D capabilities at a faster pace.research and development ;

Reaching for the stars: When does basic research collaboration between firms and academic star scientists benefit firm invention performance?

While their expertise and scientific excellence make academic star scientists attractive collaboration partners for firms, this study indicates that firms face difficulties in capturing value from collaborations with academic stars. Stars are time constrained, may be less committed to commercialization, and can be a source of undesired knowledge spillovers to other firms. The purpose of this study is to recognize the contingencies under which collaboration with star scientists is positively associated with a firm's ability to produce valuable patents (invention performance). We analyze a panel data set on the collaborations in basic research (publication data) and invention performance (patent output) of 60 prominent pharmaceutical firms. We find that basic research collaboration with academic stars is on average not associated with a performance premium above the overall positive influence of collaborating with academia. We only observe this premium if the star scientist abstains from simultaneous collaboration with other firms (‘dedication’) and extend her collaboration with the firm to involve not only basic but also applied research (‘translation’). Extending prior work that has focused on corporate star scientists, we find that if the collaboration involves an internal firm star scientist, a translational contribution of the academic star is no longer a prerequisite, and may even be detrimental to inventive performance. Our findings inform the literatures on industry-science links and firms’ (scientific) absorptive capacity by revealing the crucial contingencies for firms to benefit from partnering with the best and brightest among academic scientists

Does Spatial Ambidexterity Pay Off? On the Benefits of Geographic Proximity Between Technology Exploitation and Exploration

While most scholars tend to agree that it is worthwhile for firms to strive for ambidexterity, less consensus exists on how to organize simultaneously for exploration and exploitation. Although firms increasingly conduct R&D activities in multiple locations and countries, prior ambidexterity research has ignored a geographical dimension in explaining the ambidexterity-performance relationship. In this paper, we develop and validate the concept of spatial ambidexterity, which we define as the degree to which firms pursue technology exploration and exploitation in proximate locations. We argue that both activities benefit from proximity as firms will increase their ability to enact cross-fertilization opportunities and synergies between explorative and exploitative technological activities. Relying on a panel dataset (1995-2003) of the technological activities of 156 large R&D intensive European, U.S. and Japanese firms, we examine the degree to which technology exploration and exploitation activities are pursued simultaneously in similar or different geographical regions. Patent data are used to construct indicators of technology exploration and exploitation activities. Spatial ambidexterity is measured as the degree to which global technology exploration and exploitation activities are pursued in proximity. Our analysis confirms that firms exhibiting greater geographic proximity between technology exploration and exploitation activities display an elevated level of technological performance. Both technology activities of an explorative and exploitative nature appear to benefit from spatial proximity

Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC

Introduction: Checkpoint inhibitor (CI) therapy has revolutionized treatment for non-small cell lung cancer (NSCLC). However, a proportion of patients do not respond to CI therapy for unknown reasons. Although the current paradigm in anti-tumor immunity evolves around T cells, the presence of tertiary lymphoid structures and memory B cells has been positively correlated with response to CI therapy in NSCLC. In addition, double negative (DN) (CD27- IgD-) B cells have been shown to be abundant in NSCLC compared to healthy lung tissue and inversely correlate with the intratumoral presence of memory B cells. Nonetheless, no study has correlated DN B cells to survival in NSCLC. Methods: In this study, we evaluated the presence and phenotype of B cells in peripheral blood with flow cytometry of patients with NSCLC and mesothelioma before receiving CI therapy and correlated these with clinical outcome. Results: Non-responding patients showed decreased frequencies of B cells, yet increased frequencies of antigen-experienced CD21- DN (Atypical) B cells compared to responding patients and HC, which was confirmed in patients with mesothelioma treated with CI therapy. Conclusions: These data show that the frequency of CD21- DN B cells correlates with lack of response to CI therapy in thoracic malignancies. The mechanism by which CD21- DN B cells hamper CI therapy remains unknown. Our findings support the hypothesis that CD21- DN B cells resemble phenotypically identical exhausted B cells that are seen in chronic infection or function as antigen presenting cells that induce regulatory T cells.</p

Effects of anatomical changes on pencil beam scanning proton plans in locally advanced NSCLC patients

Daily anatomical variations can cause considerable differences between delivered and planned dose. This study simulates and evaluates these effects in spot-scanning proton therapy for lung cancer patients. Robust intensity modulated treatment plans were designed on the mid-position CT scan for sixteen locally advanced lung cancer patients. To estimate dosimetric uncertainty, deformable registration was performed on their daily CBCTs to generate 4DCT equivalent scans for each fraction and to map recomputed dose to a common frame. Without adaptive planning, eight patients had an undercoverage of the targets of more than 2GyE (maximum of 14.1GyE) on the recalculated treatment dose from the daily anatomy variations including respiration. In organs at risk, a maximum increase of 4.7GyE in the D1 was found in the mediastinal structures. The effect of respiratory motion alone is smaller: 1.4GyE undercoverage for targets and less than 1GyE for organs at risk. Daily anatomical variations over the course of treatment can cause considerable dose differences in the robust planned dose distribution. An advanced planning strategy including knowledge of anatomical uncertainties would be recommended to improve plan robustness against interfractional variations. For large anatomical changes, adaptive therapy is mandator

Heterogeneity in R&amp;D Cooperation Strategies

We explore heterogeneities in the determinants of innovating firms' decisions to engage in r&d cooperation, differentiating between four types of cooperation partners: competitors, suppliers, customers, and universities and research institutes (institutional cooperation). We use two matched waves of the dutch community innovation survey (in 1996 and 1998) and apply system probit estimation. We find that determinants of r&d cooperation differ significantly across cooperation types. The positive impact of firm size, r&d intensity, and incoming source-specific spillovers is weaker for competitor cooperation, reflecting greater appropriability concerns. Institutional spillovers are more generic in nature and positively impact all cooperation types. The results appear robust to potential simultaneity bias

An empirical analysis of patents flows and R&D flows around the world

In this article, we empirically investigate the effect of Research and Development (R&amp;D) flows on patent flows around the world. We do this using an unbalanced panel consisting primarily of Organization for Economic Co-operation and Development (OECD) countries that have both patent and R&amp;D expenditure information broken down by domestic and foreign sources. Our analysis shows that even among a fairly homogeneous group of countries, the sources of patents and R&amp;D differ substantially. Using a dynamic panel framework, we find that domestic R&amp;D per capita increases domestic patents per capita only for the European Patent Convention (EPC) countries that already have a decentralized approach to innovation. Foreign R&amp;D per capita increases foreign patents per capita in all countries even though foreign R&amp;D constitutes a very small fraction of total R&amp;D. We find that some of these differences can be attributed to the locations of the patent applications, including those to the European Patent Office (EPO), United States Patent and Trademark Office (USPTO) and triadic patent applications to the EPO, USPTO and Japan Patent Office (JPO) simultaneously